EvotecEVO
Market Cap: $1.16B
About: Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Employees: 5,022
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
40% more funds holding
Funds holding: 20 [Q1] → 28 (+8) [Q2]
1.27% more ownership
Funds ownership: 2.83% [Q1] → 4.11% (+1.27%) [Q2]
11% less capital invested
Capital invested by funds: $39.4M [Q1] → $35M (-$4.41M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Douglas Tsao 80% 1-year accuracy 4 / 5 met price target | 145%upside $8 | Buy Maintained | 15 Aug 2024 |
Financial journalist opinion
Based on 5 articles about EVO published over the past 30 days